Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study.
Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study.
复制标题
DOI：
10.1186/1758-5996-6-95
复制
发表时间：
2014
影响因子：
4.8
通讯作者：
Shimomura I
中科院分区：
文献类型：
--
作者：
Inoue K;Maeda N;Fujishima Y;Fukuda S;Nagao H;Yamaoka M;Hirata A;Nishizawa H;Funahashi T;Shimomura I
利拉鲁肽是一种胰高血糖素样肽-1（GLP-1）类似物，已显示具有多效性作用，包括体重减轻。然而，尚未在日本2型糖尿病（T2 D）受试者中阐明利拉鲁肽对体重和血糖控制的长期影响。本研究在日本T2 D受试者中研究了利拉鲁肽治疗是否可维持2年的体重减轻和降糖作用。入组的受试者为86例T2 D患者[年龄：59.8 ± 12.8岁，糖尿病病程; 15.8 ± 9.5岁，糖化血红蛋白（HbA 1c）; 8.5 ± 1.5%，体重指数（BMI）; 27.3 ± 5.4 kg/m2（15.8 - 46.5 kg/m2），平均值± SD]。在86例受试者中，25例住院患者和61例门诊患者接受了利拉鲁肽治疗，46例受试者接受了2年随访。在基线和利拉鲁肽引入后3、6、9、12和24个月测量临床参数。增加利拉鲁肽剂量和额外使用降糖药物取决于每位主治医生。在利拉鲁肽引入后1年，69例患者（80.2%）体重减轻，58例患者（67.4%）血糖控制改善。体重指数（BMI）从27.3 ± 5.4 kg/m2变为25.9 ± 4.8 kg/m2，体重降低百分比显著，并在利拉鲁肽引入后2年维持在4%以上。HbA 1c从8.5 ± 1.5%显著降低至7.7 ± 1.2%，持续2年。利拉鲁肽治疗倾向于改善脂质特征和肝酶。逐步回归分析表明，基线BMI和既往胰岛素剂量与体重减轻呈正相关，基线HbA 1c与利拉鲁肽引入后2年的HbA 1c降低呈正相关。在日本T2 D受试者中，长期利拉鲁肽治疗有效维持了体重减轻和一般血糖控制，并改善了血脂谱和肝酶。
Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been shown to possess pleiotropic effects including body weight reduction. However, long-term effect of liraglutide on body weight and glycemic control has not been elucidated in Japanese type 2 diabetes (T2D) subjects. Present study investigates whether liraglutide treatment maintains the body weight-decreasing and glucose-lowering effects for 2 years in Japanese T2D subjects. The enrolled subjects were 86 T2D patients [age; 59.8 ± 12.8 years, duration of diabetes; 15.8 ± 9.5 years, glycated hemoglobin (HbA1c); 8.5 ± 1.5%, body mass index (BMI); 27.3 ± 5.4 kg/m2 (15.8 - 46.5 kg/m2), mean ± SD]. Among 86 subjects, liraglutide was introduced in 25 inpatients and 61 outpatients, and 46 subjects were followed for 2 years. Clinical parameters were measured at baseline and 3, 6, 9, 12, and 24 months after liraglutide introduction. The increase in liraglutide dosage and the additional usage of glucose-lowering agents depended on each attending physician. At 1 year after liraglutide introduction, 69 patients (80.2%) decreased body weight and 58 patients (67.4%) improved glycemic control. Body mass index (BMI) was changed 27.3 ± 5.4 kg/m2 to 25.9 ± 4.8 kg/m2 and percent reduction of body weight was significant and maintained over 4% at 2 years after liraglutide introduction. HbA1c was significantly decreased from 8.5 ± 1.5% to 7.7 ± 1.2% for 2 years. Liraglutide treatment tended to ameliorate lipid profile and hepatic enzymes. Stepwise regression analysis demonstrated that baseline BMI and previous insulin dose were positively associated with body weight reduction and baseline HbA1c was positively associated with reduction of HbA1c at 2 years after liraglutide introduction. Long-term liraglutide treatment effectively maintained the reduction of body weight and the fair glycemic control, and also improved lipid profile and liver enzymes in Japanese T2D subjects.
登录
查看更多内容
影响因子：
5.9
作者：
Chilton, Robert;Wyatt, Jamison;Lujan, Michael
通讯作者：
Lujan, Michael
影响因子：
3.8
作者：
Fadini, Gian Paolo;Simioni, Natalino;Avogaro, Angelo
通讯作者：
Avogaro, Angelo
影响因子：
7.7
作者：
Arakawa M;Mita T;Azuma K;Ebato C;Goto H;Nomiyama T;Fujitani Y;Hirose T;Kawamori R;Watada H
通讯作者：
Watada H
影响因子：
16.2
作者：
Wing RR;Lang W;Wadden TA;Safford M;Knowler WC;Bertoni AG;Hill JO;Brancati FL;Peters A;Wagenknecht L;Look AHEAD Research Group
通讯作者：
Look AHEAD Research Group
DOI：
10.1111/j.1463-1326.2010.01356.x
发表时间：
2011-04
期刊：
Diabetes, obesity & metabolism
影响因子：
--
作者：
Garber A;Henry RR;Ratner R;Hale P;Chang CT;Bode B;LEAD-3 (Mono) Study Group
通讯作者：
LEAD-3 (Mono) Study Group